miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance

Jiansheng Lin1, Xinyang Zheng1, Xikun Tian2

  • 1Department of cardiothoracic surgery, The First Hospital of Putian City, No 449 Nanmen West Road, 351100, Chengxiang District, Putian City, Fujian Province, China.

Journal of Cancer
|May 6, 2022
PubMed

Insights

MicroRNA-1247-3p (miR-1247-3p) inhibits lung adenocarcinoma cell migration and chemoresistance by targeting STAT5A. This microRNA shows potential as a novel therapeutic target for lung adenocarcinoma (LUAD).

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Lung adenocarcinoma (LUAD) research has advanced, yet mechanisms of cancer cell migration and chemoresistance remain unclear.
  • Understanding the role of specific microRNAs is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the function and mechanism of miR-1247-3p in lung adenocarcinoma.
  • To explore its potential as a therapeutic target for LUAD.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) for miR-1247-3p and STAT5A expression.
  • Transwell assays for cell migration and drug sensitivity tests (Docetaxel, Doxorubicin, Gefitinib).
  • Bioinformatic analysis (DIANA, miRDB, TargetScan) and dual-luciferase reporter assays to identify and verify STAT5A as a direct target.

Main Results:

  • miR-1247-3p expression was significantly downregulated in LUAD tissues and cell lines, particularly in advanced stages.
  • Overexpression of miR-1247-3p inhibited LUAD cell migration and enhanced sensitivity to chemotherapy.
  • miR-1247-3p directly targets the 3' untranslated region (UTR) of STAT5A mRNA, regulating its expression.

Conclusions:

  • miR-1247-3p acts as a tumor suppressor in LUAD by inhibiting cell migration and chemoresistance through STAT5A.
  • miR-1247-3p represents a promising therapeutic target for lung adenocarcinoma treatment.

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K